Education
About Us
Working with TipRanks
Follow Us
Immunotech Biopharm Ltd (HK:6978)
:6978
6978 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.50 - HK$6.15
Previous CloseN/A
Volume50.00K
Average Volume (3M)1.61M
Market Cap
HK$2.45B
Enterprise ValueHK$1.56B
Total Cash (Recent Filing)HK$57.49M
Total Debt (Recent Filing)HK$116.46M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Mar 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding514,584,000
10 Day Avg. Volume1,323,838
30 Day Avg. Volume1,611,105
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immunotech Biopharm Ltd News
6978 FAQ
What was Immunotech Biopharm Ltd’s price range in the past 12 months?
Immunotech Biopharm Ltd lowest stock price was HK$1.50 and its highest was HK$6.15 in the past 12 months.
What is Immunotech Biopharm Ltd’s market cap?
Immunotech Biopharm Ltd’s market cap is HK$2.45B.
When is Immunotech Biopharm Ltd’s upcoming earnings report date?
Immunotech Biopharm Ltd’s upcoming earnings report date is Mar 20, 2026 which is in 182 days.
How were Immunotech Biopharm Ltd’s earnings last quarter?
Immunotech Biopharm Ltd released its earnings results on Aug 20, 2025. The company reported -HK$0.27 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.27.
Is Immunotech Biopharm Ltd overvalued?
According to Wall Street analysts Immunotech Biopharm Ltd’s price is currently Overvalued.
Does Immunotech Biopharm Ltd pay dividends?
Immunotech Biopharm Ltd does not currently pay dividends.
What is Immunotech Biopharm Ltd’s EPS estimate?
Immunotech Biopharm Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunotech Biopharm Ltd have?
Immunotech Biopharm Ltd has 514,584,000 shares outstanding.
What happened to Immunotech Biopharm Ltd’s price movement after its last earnings report?
Immunotech Biopharm Ltd reported an EPS of -HK$0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.769%.
Which hedge fund is a major shareholder of Immunotech Biopharm Ltd?
Currently, no hedge funds are holding shares in HK:6978
Immunotech Biopharm Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.65%
12-Months-Change
Fundamentals
Return on Equity
-228.99%
Trailing 12-Months
Asset Growth
-30.74%
Trailing 12-Months
Company Description
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd (6978) is a biopharmaceutical company primarily engaged in the research, development, and commercialization of cellular immunotherapy products. The company focuses on creating innovative treatments for cancer, leveraging its expertise in T-cell immunotherapy. Immunotech Biopharm Ltd operates within the biotechnology sector and aims to provide effective therapeutic solutions to improve patient outcomes.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
SinoMab Bioscience Ltd.
―
Zhaoke Ophthalmology Ltd.
―